Difference between revisions of "Team:Amoy/Project/Discussion"

Line 118: Line 118:
 
<!--word-->
 
<!--word-->
 
<div id="title" class="col-md-9">
 
<div id="title" class="col-md-9">
<p id="title_p">PROJECT DESCRIPTION</p>
+
<p id="title_p">DISCUSSION</p>
<p class="main_p">L-tert-leucine, an unnatural amino acid, plays an important role in the pharmaceutical, agrochemical, food additives and cosmetic industry. With its special importance, many methodologies, including chemical and biological resolutions, were developed for its preparation in the past decades. Chemical resolution could be easily carried out on a large scale, however, the tedious process in low yield and the difficulties in the racemization of the opposite enantiomer were also observed. Biocatalytic protocols, which can be conducted under mild conditions with high selectivity, usually offer greater benefits than chemical procedures and thus gain more and more attention from organic chemist. However, most of these biological resolution procedures are tedious and possess an inherent 50% yield limit.</br></br>
+
<p class="main_p">From March to September, nearly 200 days of learning and working, we made so much of mistakes in lab work but eventually obtained ideal data and results. From the results we had, we made following analysis of our system. See more data and results please click here.</br></p>
  
In order to solve the problem, scientists developed enzymatic reductive amination to produce L-tert-leucine by using leucine dehydrogenase and formate dehydrogenase. This technology greatly improve the yield and excellent enantiomeric excess of L-tert-leucine. It is regarded to be one of the most efficient routes.
+
<h1 class="main_h1">Whole-cell biocatalyst</h1>
</p>
+
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/f/f7/Amoy-Project_Overview_figure1.jpg" style="width: 80%;" />
+
<p class="main_p">Nowadays, there are mainly two methods applying to produce L-tert-leucine, isolated enzymes and whole-cell biocatalyst.</br></br>
  
<p class="main_p"></br></br>Owing to different activity of leucine dehydrogenase and formate dehydrogenase, the NADH consumption rate does not equal to its regeneration. Therefore, it is necessary to add excess NADH. the cofactor-NADH is an pretty expensive raw material, which will make the mass production of L-tert-leucine not cost-effective.</br></br>
+
However, the use of isolated enzymes can be disadvantageous because of laborious isolation and purification of the enzymes and also often a reduced stability under process conditions. Then, because leucine dehydrogenase and formate dehydrogenase have different enzyme activities, we have to add different wet biomass of two E.coli. If this method is applied into industrial production, it will cost more labors and machines. Furthermore, proteins expressions require more than twice raw materials by adopting this method. By choosing one circuit containing two genes, production becomes easier and cheaper because it simplify the production process and save costs. To begin with, there is not only no need to purify enzymes, but also can use host cells intensive mixing them and keep the enzyme activity. What`s more, only one fermentation required will save more time and raw materials.</br></br>
  
The circuits with LeuDH and with FDH were inserted into two E.coli separately. Then they add different wet biomass of two E.coli. They hope to keep the activity of two enzyme equal through this method. Researchers using isolated enzymes find it disadvantageous because enzymes are easily destabilized in the isolation and purification process.</br></br>
+
As for the whole-cell biocatalyst, the coexpression was realized by location of the two related genes on two plasmids with different copy numbers, producing LeuDH and FDH at different levels. Obviously, compared with isolated enzymes, whole-cell biocatalysts could stabilize enzymes and reduce costs of production. However, whole-cell biocatalyst also has shortcomings. Firstly, it is inconvenient to transform two plasmids into one host cell. Secondly, we need to add two kinds of antibiotics into culture medium due to the different resistances of plasmids which will make host cells hard to grow. Thirdly, using substrate concentrations of 500mM or higher, revealed a non-satisfactory reaction course, indicating significant inhibitions effects. The activities of two enzymes are both inhibited. By choosing one circuit containing two genes, we can obtain a more stable protein expression system and simplify the transformation process at the same time. More importantly, activities of two enzymes improve significantly.</br></br>
  
Then researchers plan to use whole-cell biocatalyst to stabilize enzymes and reduce the need of cofactor NADH. They envisaged that a promising strategy for a successful co-expression could be based on the same inducible promoter for both genes but located on two E.coli plasmids with different copy numbers, producing LeuDH and FDH on a different level. FDH was inserted in the plasmid with the higher copy number, while LeuDH was inserted in the medium copy number plasmid. We hope to regulate the copy number of plasmid to ensure the continuous recycling of the cofactor NADH. Presumably, this was achieved by a higher production of FDH compared to LeuDH due to the higher copy number vector for the FDH gene. Furthermore, this LeuDH/FDH-strain is suitable for high-cell density fermentation. Compared with isolated enzymes,whole cell-catalyzed asymmetric process has many advantages, such as simple, efficient, environmentally and economically attractive. However, researchers also find that using substrate concentrations of 500mM or higher, revealed a non-satisfactory reaction course, indicating significant inhibitions effects. The activity of two enzymes are both inhibited. Obviously, successful coexpression of two genes is still a challenge for scientists.</br></br>
+
In conclusion, our team optimize the above two methods through putting two genes into one plasmid. It only requires one fermentation run and simple cell separation as a concentration step. Meanwhile, activities of enzymes improve. In other words, with the help of our engineering bacteria, cost will be saved and output is expected to improve.</br>
 
+
So when we started to do our project though biological method, the problems are clear. One is researchers find it disadvantageous using isolated enzymes because enzymes are easily destabilized in the isolation and purification process. What's more, owing to different activities of leucine dehydrogenase and formate dehydrogenase, the NADH consumption rate does not equal to its regeneration. Therefore, it is necessary to add excess NADH. Whereas the cofactor-NADH is a pretty expensive raw material, which will make the mass production of L-tert-leucine not cost-effective. Given all these problems we plan to insert leudh and fdh to one circuit and use whole-cell biocatalyst to stabilize enzymes.
+
 
</p>
 
</p>
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/0/06/Amoy-Project_Overview_figure2.png" style="width: 100%;" />
+
<h1 class="main_h1">Different strength of RBS</h1>
  
<p class="main_p"></br></br>But why do we choose one circuit containing two genes and use whole-cell catalysts? Firstly, only one fermentation is required to produce the biocatalyst compared to two separate fermentations to clone cells containing LeuDH and FDH respectively, which is much more convenient. Secondly, transforming two plasmids with different resistance to one bacterium will make the E.coli hard to grow. Thirdly, the biocatalyst is suitable for high-cell density fermentations. No isolation and purification of the enzymes is required. Fourthly, whole-cell catalysts can achieve the effect of premix, which help to make the two enzymes cooperate well. Fifthly, it’s good for us to control variable in one cell. Last but not least, the most attractive thing is none or only very little external cofactor is required, because it is already contained in the whole-cell biocatalyst. In a word, the method we adopt not only can save a lot of cost but also can make it easy for us to adjust the expression level of 2 genes.</br></br>
+
<p class="main_p">The main purpose of our project this year is to make co-factor NADH self-sufficient in our redox reactions by using different strength of RBS. The expected result is that we find the best ratio of the two enzymes working together, leading to the equivalence of consumption rate and regeneration rate. Ribosome binding site plays an important role in regulating the process of protein translation.Different RBSs bind ribosomes with different efficiencies.Clearly we can regulate the yield of the two enzymes needed-LeuDH and FDH by using various kind of RBSs.</br></br>
  
Here comes our project. The whole plan is to regulate the efficiency of ribosome binding site (RBS) to control the strength of leucine dehydrogenase and formate dehydrogenase. With the help of mathematical modeling, the most suitable efficiency of RBS of leucine dehydrogenase will be obtained. Consequently, the cofctor NADH can be self-sufficient as shown in this cycle.</br></br>
+
Consequently,we constructed three different plasmids with three types of RBS, B0030,B0032,and B0034. B0034 is stronger than B0030 and B0032 is the weakest. The second enzyme FDH with lower enzyme activity is equipped with the strongest RBS-B0034, the regulation lies on the first enzyme-LeuDH.As the result of HPLC shows,LeuDH expression decreased under the regulation of B0032 as expected.
 +
</p>
 +
 
 +
<img class="main_img" src="https://static.igem.org/mediawiki/2015/4/4d/Amoy-Project_Discussion_figure1.png" style="width: 100%;" />
  
To achieve our goal, we got two gene circuits, one contains LeuDH gene and the other one contains FDH gene. We conbined them together and transformed the long circuit to Ecoli so that two genes can express independently according to the RBS strength we arranged. After some time, the Ecoli will be broken and two enzymes are realeasd. At that moment we add the substrate------Trimethylpyruvic acid and ammonium formate to the system, so the cyclic catalysis begins and the leucine will be produced.
+
<p class="main_p"></br></br>However, the parts of different RBS we get from the iGEM registry cannot meet our demands,because these parts are not continuously adjustable.That means we may not be able to make the reaction cycle one hundred percent self-sufficient or in another way, no perfect effects of productivity.what should we do next will be discussed in the future work.
 
</p>
 
</p>
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/5/56/Amoy-Project_Overview_figure3.jpg" style="width: 100%;" />
+
<h1 class="main_h1">Different Concentration of IPTG</h1>
  
<p class="main_p"></br></br>We have totally constructed 3 circuits which contain different RBS pairs. Because the catalytic efficiency of FDH is much more weaker, we use the most strong RBS------B0034 for FDH, and we change the RBS for LeuDH ------B0032、B0030、B0034. As we expect, the data of expression characterization showed the circuit with B0030 and B0034 has the highest expression efficiency.
+
<p class="main_p">IPTG(Isopropyl β-D-1-Thiogalactopyranoside)is known to be a highly stable molecule in solution at room temperature and in bacterial cultures under commonly used conditions for recombinant protein production.[1]</br></br>
 +
 
 +
After reading some relevant review articles, we found that IPTG (Isopropyl β-D-1-Thiogalactopyranoside) is an effective inducer of protein expression. For example, it can promote the expression of a thermostable amidase in recombinant Escherichia coli [2] and the GST- GnRH/ TRS gene[3]So we design an experiment which using different concentration of IPTG to explore whether IPTG promote the expression of our gene circuit or not. After experiments, we found that it can increase the expression of gene by determining the enzyme activity. And we found the optimal concentration of IPTG.
 
</p>
 
</p>
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/c/ce/Amoy-Project_Overview_figure4.png" style="display: inline-block; float: left;" />
+
<h1 class="main_h1">Adaptability of cofactor regeneration systems</h1>
<img class="main_img" src="https://static.igem.org/mediawiki/2015/7/70/Amoy-Project_Overview_figure5.png" style="display: inline-block; float: right;" />
+
<img class="main_img" src="https://static.igem.org/mediawiki/2015/b/ba/Amoy-Project_Overview_figure6.png" />
+
  
<h2 class="main_h2"></br>Reference:</h2>
+
<p class="main_p">Whole-cell biocatalysts based on cofactor regeneration system have showed board future throughout our project study. Recently [4] genetic engineering has made it possible to construct a new yeast strain to simplify the use of co- factor-requiring enzymes by introducing heterologous genes. [5]Thereby we demonstrate nearly all cofactor regeneration systems could be suitable under our framework.</br></br>
 +
 
 +
For example, NADH Oxidase is a kind of oxidoreductase that catalyzes the oxidation of NADH by oxygen to yield H2O and NAD+. NOX can be used to the regeneration of NADH. glycerol dehydrogenase is an enzyme in the oxidoreductase family that utilizes the NAD+ to catalyze the oxidation of glycerol to form glycerone (dihydroxyacetone). We will engineer fusion enzyme (GDH-NOX) of glycerol dehydrogenase and NADH oxidase. The fusion enzyme may successfully express in Escherichia coli and characterize.</br></br>
 +
 
 +
A variety of potential useful enzymes require nicotinamide cofactors. And cofactor regeneration system played an important role in reducing the costs. Apart from the case of NADH Oxidase and glycerol dehydrogenase, our framework coupled with different enzymes could be perfectly optimized by different strengthen of ribosome binding site, which would be a huge progress in whole-cell biocatalyst.
 +
</p>
 +
 
 +
<h1 class="main_h1">Reference</h1>
  
 
<p class="main_p">
 
<p class="main_p">
[1] Harald Gro¨ ger, Oliver May,Helge Werner,Anne Menzel,and Josef Altenbuchner</br>
+
[1] Harald Gro¨ ger, Oliver May, Helge Werner, Anne Menzel,and Josef Altenbuchner <strong>A “Second-Generation Process” for the Synthesis ofL-Neopentylglycine:Asymmetric Reductive Amination Using a Recombinant Whole Cell Catalys</strong>. Organic process research&development 2006, 10, 666-669</br></br>
A “Second-Generation Process” for the Synthesis ofL-Neopentylglycine:Asymmetric Reductive Amination Using a Recombinant Whole Cell Catalys. Organic process research&development 2006,10,666-669</br>
+
[2] Menzel, Anne, Werner, Helge, Altenbuchner, Josef,Gr?ger, Harald.From <strong>enzymes to "designer bugs" in reductive amination: A new process for the synthesis of L-tert-leucine using a whole cell-catalyst</strong>. Engineering in Life Sciences.</br></br>
[2] Menzel, Anne,Werner, Helge,Altenbuchner, Josef,Gr?ger, Harald.From enzymes to "designer bugs" in reductive amination: A new process for the synthesis of L-tert-leucine using a whole cell-catalyst. Engineering in Life Sciences. 2004</br>
+
 
[3] Jin, Jian-Zhong,Chang, Dong-Liang,Zhang, Jie.Discovery and application of new bacterial strains for asymmetric synthesis of L-tert-butyl leucine in high enantioselectivity. Applied Biochemistry and Biotechnology.2011</br>
+
[3] Michael Schwarm. <strong>Application of Whole-Cell Biocatalysts in the Manufacture of Fine Chemicals Michael</strong>.</br></br>
[4]Eun young Hong,Minho Cha,Hyungdon Yun,Byung-Gee Kim. Asymmetric synthesis of L-tert-leucine and L-3-hydroxyadamantyglycine using branched chain aminotransferase.   Journal of Molecular Catalysis B:Enzymatic 66(2010)228-233</br>
+
 
[5]Jing Li, Jiang Pan, Jie Zhang, Jian-He Xu  Stereoselective synthesis of L-tert-leucine by a newly cloned leucine dehydrogenase from Exiguobacterium sibiricum.</br>
+
[4] Katoh R, Nagata S, Misono H. <strong>Cloning and sequencing of the leucine dehydrogenase gene from Bacillus sphaericus IFO 3525 and importance of the C-terminal region for the enzyme activity</strong>[ J]. Molecular Catalysis B: Enzymatic, 2003, 23 (2):239.</br></br>
Journal of Molecular Catalysis B:Enzymatic 105(2014)11-17</br>
+
 
[6]Jian-Zhong, JinDong-Liang, Chang Jie Zhang  Discovery and application of new bacterial strains for asymmetric synthesis of L-tert-butyl leucine in high enantioselectivity.    Appl Biochem Biotechnol (2011) 164:376-385</br>
+
[5] U.Kragl, D. Vasic-Racki, C. Wandrey. <strong>Continuous production of L-tert-leucine in series of two enzyme membrane reactors</strong>. Bioprocess Engineering 14 (z996) z9a 297.</br></br>
[7]Weiming Liu, Jixing Luo, Xiaojian Zhuang, Wenhe Shen, Yang Zhang, SHuang Li, Yi Hu, He Huang  Efficient preparation of enantiopure L-tert-leucine through immobilized penicillin G acylase catalyzed kinetic resolution in aqueous medium.</br>
+
 
Biochemical Engineering Journal 83(2014) 116-120</br>
+
[1] Nicolo’ Politi (1) (2);Lorenzo Pasotti (1) (2);Susanna Zucca (1) (2);Michela Casanova (1) (2);Giuseppina Micoli (3);Maria Gabriella Cusella De Angelis (2);Paolo Magni (1) (2)</br>
 +
<strong>Half-life measurements of chemical inducers for recombinant gene expression</strong></br>
 +
Journal of Biological Engineering,2014,8,(1):1-22</br></br>
 +
 
 +
[2] Oluwafemi A. Olaofea, Stephanie G. Burtona,1, Don A. Cowanb, Susan T.L. Harrisona,∗</br>
 +
<strong>Improving the production of a thermostable amidase through optimising IPTG</strong></br>
 +
<strong>induction in a highly dense culture of recombinantEscherichia coli</strong></br>
 +
Biochemical Engineering Journal52 (2010) 19–24</br></br>
 +
 
 +
[3] JN Yuan-chang1, 2, LU L i3, SU Xiao-yan4, etal</br>
 +
<strong>Effect of induce concentration, time and temperature of IPTG on the expression of the GST- GnRH/ TRS gene</strong> Heilongjiang Animal Science And Veterinary Medicine,2006,(8)</br></br>
 +
 
 +
[4] Stewart JD (2000) Curr Opin Biotechnol 11:363</br></br>
 +
 
 +
[5]R. Wichmann · D. Vasic-Racki <strong>Cofactor Regeneration at the Lab Scale</strong> Adv Biochem Engin/Biotechnol (2005) 92: 225 – 260
 +
 
 +
 
 +
 
 
</p>
 
</p>
  

Revision as of 10:19, 6 September 2015

Aomy/Project

DISCUSSION

From March to September, nearly 200 days of learning and working, we made so much of mistakes in lab work but eventually obtained ideal data and results. From the results we had, we made following analysis of our system. See more data and results please click here.

Whole-cell biocatalyst

Nowadays, there are mainly two methods applying to produce L-tert-leucine, isolated enzymes and whole-cell biocatalyst.

However, the use of isolated enzymes can be disadvantageous because of laborious isolation and purification of the enzymes and also often a reduced stability under process conditions. Then, because leucine dehydrogenase and formate dehydrogenase have different enzyme activities, we have to add different wet biomass of two E.coli. If this method is applied into industrial production, it will cost more labors and machines. Furthermore, proteins expressions require more than twice raw materials by adopting this method. By choosing one circuit containing two genes, production becomes easier and cheaper because it simplify the production process and save costs. To begin with, there is not only no need to purify enzymes, but also can use host cells intensive mixing them and keep the enzyme activity. What`s more, only one fermentation required will save more time and raw materials.

As for the whole-cell biocatalyst, the coexpression was realized by location of the two related genes on two plasmids with different copy numbers, producing LeuDH and FDH at different levels. Obviously, compared with isolated enzymes, whole-cell biocatalysts could stabilize enzymes and reduce costs of production. However, whole-cell biocatalyst also has shortcomings. Firstly, it is inconvenient to transform two plasmids into one host cell. Secondly, we need to add two kinds of antibiotics into culture medium due to the different resistances of plasmids which will make host cells hard to grow. Thirdly, using substrate concentrations of 500mM or higher, revealed a non-satisfactory reaction course, indicating significant inhibitions effects. The activities of two enzymes are both inhibited. By choosing one circuit containing two genes, we can obtain a more stable protein expression system and simplify the transformation process at the same time. More importantly, activities of two enzymes improve significantly.

In conclusion, our team optimize the above two methods through putting two genes into one plasmid. It only requires one fermentation run and simple cell separation as a concentration step. Meanwhile, activities of enzymes improve. In other words, with the help of our engineering bacteria, cost will be saved and output is expected to improve.

Different strength of RBS

The main purpose of our project this year is to make co-factor NADH self-sufficient in our redox reactions by using different strength of RBS. The expected result is that we find the best ratio of the two enzymes working together, leading to the equivalence of consumption rate and regeneration rate. Ribosome binding site plays an important role in regulating the process of protein translation.Different RBSs bind ribosomes with different efficiencies.Clearly we can regulate the yield of the two enzymes needed-LeuDH and FDH by using various kind of RBSs.

Consequently,we constructed three different plasmids with three types of RBS, B0030,B0032,and B0034. B0034 is stronger than B0030 and B0032 is the weakest. The second enzyme FDH with lower enzyme activity is equipped with the strongest RBS-B0034, the regulation lies on the first enzyme-LeuDH.As the result of HPLC shows,LeuDH expression decreased under the regulation of B0032 as expected.



However, the parts of different RBS we get from the iGEM registry cannot meet our demands,because these parts are not continuously adjustable.That means we may not be able to make the reaction cycle one hundred percent self-sufficient or in another way, no perfect effects of productivity.what should we do next will be discussed in the future work.

Different Concentration of IPTG

IPTG(Isopropyl β-D-1-Thiogalactopyranoside)is known to be a highly stable molecule in solution at room temperature and in bacterial cultures under commonly used conditions for recombinant protein production.[1]

After reading some relevant review articles, we found that IPTG (Isopropyl β-D-1-Thiogalactopyranoside) is an effective inducer of protein expression. For example, it can promote the expression of a thermostable amidase in recombinant Escherichia coli [2] and the GST- GnRH/ TRS gene[3]So we design an experiment which using different concentration of IPTG to explore whether IPTG promote the expression of our gene circuit or not. After experiments, we found that it can increase the expression of gene by determining the enzyme activity. And we found the optimal concentration of IPTG.

Adaptability of cofactor regeneration systems

Whole-cell biocatalysts based on cofactor regeneration system have showed board future throughout our project study. Recently [4] genetic engineering has made it possible to construct a new yeast strain to simplify the use of co- factor-requiring enzymes by introducing heterologous genes. [5]Thereby we demonstrate nearly all cofactor regeneration systems could be suitable under our framework.

For example, NADH Oxidase is a kind of oxidoreductase that catalyzes the oxidation of NADH by oxygen to yield H2O and NAD+. NOX can be used to the regeneration of NADH. glycerol dehydrogenase is an enzyme in the oxidoreductase family that utilizes the NAD+ to catalyze the oxidation of glycerol to form glycerone (dihydroxyacetone). We will engineer fusion enzyme (GDH-NOX) of glycerol dehydrogenase and NADH oxidase. The fusion enzyme may successfully express in Escherichia coli and characterize.

A variety of potential useful enzymes require nicotinamide cofactors. And cofactor regeneration system played an important role in reducing the costs. Apart from the case of NADH Oxidase and glycerol dehydrogenase, our framework coupled with different enzymes could be perfectly optimized by different strengthen of ribosome binding site, which would be a huge progress in whole-cell biocatalyst.

Reference

[1] Harald Gro¨ ger, Oliver May, Helge Werner, Anne Menzel,and Josef Altenbuchner A “Second-Generation Process” for the Synthesis ofL-Neopentylglycine:Asymmetric Reductive Amination Using a Recombinant Whole Cell Catalys. Organic process research&development 2006, 10, 666-669

[2] Menzel, Anne, Werner, Helge, Altenbuchner, Josef,Gr?ger, Harald.From enzymes to "designer bugs" in reductive amination: A new process for the synthesis of L-tert-leucine using a whole cell-catalyst. Engineering in Life Sciences.

[3] Michael Schwarm. Application of Whole-Cell Biocatalysts in the Manufacture of Fine Chemicals Michael.

[4] Katoh R, Nagata S, Misono H. Cloning and sequencing of the leucine dehydrogenase gene from Bacillus sphaericus IFO 3525 and importance of the C-terminal region for the enzyme activity[ J]. Molecular Catalysis B: Enzymatic, 2003, 23 (2):239.

[5] U.Kragl, D. Vasic-Racki, C. Wandrey. Continuous production of L-tert-leucine in series of two enzyme membrane reactors. Bioprocess Engineering 14 (z996) z9a 297.

[1] Nicolo’ Politi (1) (2);Lorenzo Pasotti (1) (2);Susanna Zucca (1) (2);Michela Casanova (1) (2);Giuseppina Micoli (3);Maria Gabriella Cusella De Angelis (2);Paolo Magni (1) (2)
Half-life measurements of chemical inducers for recombinant gene expression
Journal of Biological Engineering,2014,8,(1):1-22

[2] Oluwafemi A. Olaofea, Stephanie G. Burtona,1, Don A. Cowanb, Susan T.L. Harrisona,∗
Improving the production of a thermostable amidase through optimising IPTG
induction in a highly dense culture of recombinantEscherichia coli
Biochemical Engineering Journal52 (2010) 19–24

[3] JN Yuan-chang1, 2, LU L i3, SU Xiao-yan4, etal
Effect of induce concentration, time and temperature of IPTG on the expression of the GST- GnRH/ TRS gene Heilongjiang Animal Science And Veterinary Medicine,2006,(8)

[4] Stewart JD (2000) Curr Opin Biotechnol 11:363

[5]R. Wichmann · D. Vasic-Racki Cofactor Regeneration at the Lab Scale Adv Biochem Engin/Biotechnol (2005) 92: 225 – 260

CONTACT US

Email: igemxmu@gmail.com

Website: 2015.igem.org/Team:Amoy

Address: Xiamen University, No. 422, Siming South Road, Xiamen, Fujian, P.R.China 361005